CARIS LIFE SCIENCES, INC. vs NATERA, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CAI and NTRA diverge most: on operating margin, CAI reads 2.4% and NTRA reads -13.4%; on return on invested capital, CAI reads 2.0% and NTRA reads -13.8%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | CAI | NTRA |
|---|---|---|
| Price | $15.68 | $267.71 |
| Market cap | $4.4B | $37.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| Implied growth (priced in) | +33.0% | — |
| P/B | 7.47 | 21.35 |
| P/S | 6.03 | 15.15 |
| EV/EBITDA | 82.5 | — |
| Revenue growth | +91.2% | +36.4% |
| Operating margin | 2.4% | -13.4% |
| Net margin | -20.5% | -9.1% |
| Return on equity | -25.4% | -12.8% |
| Return on assets | -12.9% | -8.7% |
| Return on invested capital | 2.0% | -13.8% |
| FCF yield | 2.8% | 0.3% |
| Debt / equity | 0.64 | 0.05 |
| Current ratio | 7.05 | 2.96 |
| Altman Z (solvency) | 3.15 | 5.81 |
| Piotroski F (quality) | 5 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.